NOV 28, 2018
Inherited Disease, Pediatric Ophth/Strabismus, Retina/Vitreous, Vitreoretinal Diseases
Dr. Tahira Scholle demonstrates the administration of a subretinal injection of Luxturna (voretigene neparvovec-ryzyl), the first FDA-approved gene therapy for inherited retinal disease. The patient is a 6-year-old girl with biallelic mutation of RPE65. Dr. Scholle includes several tips for a successful injection of the gene therapy, which costs $425,000 per eye.
Relevant Financial Disclosures: None